{"nctId":"NCT00642304","briefTitle":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","startDateStruct":{"date":"2008-03-27","type":"ACTUAL"},"conditions":["Anemia"],"count":20,"armGroups":[{"label":"methoxy polyethylene glycol-epoetin beta","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]"]}],"interventions":[{"name":"methoxy polyethylene glycol-epoetin beta [C.E.R.A.]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic renal anemia\n* Stable darbepoetin alfa or epoetin beta therapy for past 8 weeks\n\nExclusion Criteria:\n\n* Transfusion of red blood cells during previous 8 weeks\n* Poorly controlled hypertension requiring interruption of epoetin treatment in previous 6 months\n* Acute or chronic bleeding requiring therapy within previous 8 weeks","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy Evaluation Period (EEP)","description":"The reference Hb value was taken as the time adjusted average of all Hb assessments during the Stability Verification Period (SVP) (Week -4 to Week 0). EEP was from Week 16 to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Hb Concentration Between SVP and the EEP","description":"The mean change in the time-adjusted average Hb concentration between the two study periods SVP (Baseline) and EEP is presented. The SVP was defined as Week -4 to Week 0. The EEP was defined as Week 16 to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Hb Concentration Within Hb Range 10.5 to 12.5 g/dL During the EEP","description":"The EEP was defined as Week 16 to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent in Hb Range of 10.5 to 12.5 g/dL During the EEP","description":"The EEP was defined as Week 16 to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":"24.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Blood Transfusion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Dose Adjustment","description":"A dose adjustment was defined as a change versus the preceding dose. It included dose increase and dose reduction from the dose given at Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":20},"commonTop":["Hypertension","Cystitis","Blood phosphorus increased","Blood potassium increased","Renal failure chronic"]}}}